Trademark Overview
On Friday, May 2, 2025, a trademark application was filed for XBALCI with the United States Patent and Trademark Office. The USPTO has given the XBALCI trademark a serial number of 99166872. The federal status of this trademark filing is NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER as of Friday, May 2, 2025. This trademark is owned by Glaxo Group Limited. The XBALCI trademark is filed in the Pharmaceutical Products category with the following description:
Vaccines; Anti-infectives; Pharmaceutical preparations for the treatment of damaged skin and tissue, pain, inflammation, obesity, and infectious diseases; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, hematological, bacterial, respiratory, neurological, gastrointestinal, dermatological, psychiatric, and immune system related diseases and disorders; Pharmaceutical preparations for the prevention of infectious diseases